Skip to main content

Table 1 Demographics of SLE patients, normal controls and disease controls*

From: Olf1/EBF associated zinc finger protein interfered with antinuclear antibody production in patients with systemic lupus erythematosus

 

SLE patients (n = 40)

Normal controls (n = 30)

Disease controls (n = 18)+

Age, years

33.48 ± 2.11 (14 to 70)

29.23 ± 1.13 (19 to 42)

38.39 ± 2.02 (18 to 54)

Female gender

33 (82.5%)

24 (80.0%)

17 (94.1%)

Disease duration, years

5.91 ± 0.94 (0.08 to 20)

  

SLEDAI score

7.70 ± 0.90 (1 to 27)

  

Autoantibodies

   

   Anti-dsDNA

15 (37.5%)

  

   Anti-Sm

19 (47.5%)

  

   Anti-SSA

18 (45.0%)

  

   Anti-SSB

14 (35.0%)

  

   Anti-U1RNP

9 (22.5%)

  
  1. * Values are shown by mean ± SEM (range) or number (percentage). There were no significant differences between patients with systemic lupus erythematosus (SLE) and normal controls or disease controls in terms of age and gender.
  2. +Consisted of 18 patients with rheumatoid arthritis. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us